Sellas Life Sciences Group (SLS)
NASDAQ:SLS
Want to see SLS full AI Analyst Report?
SLS Stock Chart & Stats
$4.11
-$0.10(-9.43%)
At close: 4:00 PM EST
$4.11
-$0.10(-9.43%)
Day’s Range― - ―
52-Week Range$1.39 - $9.51
Previous CloseN/A
Volume1.43M
Average Volume (3M)9.46M
Market Cap
$1.46B
Enterprise Value$1.22B
Total Cash (Recent Filing)$107.20M
Total Debt (Recent Filing)$871.00K
Price to Earnings (P/E)―
Beta0.91
Next Earnings
Aug 06, 2026EPS Estimate
-0.05Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-0.23
Shares Outstanding186,032,580
10 Day Avg. Volume6,991,550
30 Day Avg. Volume9,464,046
Financial Highlights & Ratios
PEG Ratio0.31
Price to Book (P/B)5.80
Price to Sales (P/S)0.00
P/FCF Ratio-14.48
Enterprise Value/Market Cap0.84
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/Ebitda-54.52
Forecast
1Y Price Target
$10.00Price Target Upside143.31% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering2
EPS Forecast (FY)-0.28
Revenue Forecast (FY)$36.13M
Bulls Say, Bears Say
Bulls Say
Balance Sheet StrengthThe company reports minimal total debt (~$0.9M) and materially improved equity (over $107M). For a clinical-stage biotech, low leverage and strengthened capitalization provide durable financial flexibility to fund trials, pursue partnerships, or withstand setbacks without heavy interest burden.
Improved Liquidity Via Warrant ExercisesWarrant exercises increased cash reserves to roughly $107.1M and added ~ $28.7M in proceeds, materially improving near-term runway. Sustained liquidity reduces immediate financing pressure, enabling multi-quarter clinical programs and milestone execution without urgent capital raises.
Focused Oncology PipelineSELLAS maintains a concentrated clinical-stage pipeline focused on therapeutic cancer vaccines (GPS, NP-S) targeting hematologic and HER2-expressing cancers. This targeted R&D approach aligns with durable structural demand for immunotherapies and offers clear commercial upside if pivotal trials succeed.
Bears Say
No Meaningful RevenueThe company has generated essentially no product revenue across recent years while reporting a TTM net loss near $29.5M. This structural absence of operating income means the business cannot self-fund development or commercialization, keeping long-term viability tied to successful trial outcomes and external capital.
Persistent Cash BurnTrailing twelve‑month operating and free cash flow are deeply negative (~-$28.2M) with sharp free cash flow deterioration. Ongoing cash burn increases the probability of repeated financings, constrains strategic optionality, and raises execution risk for multi-stage clinical programs without clear path to revenue.
Shareholder Dilution RiskThe company has repeatedly relied on warrant exercises and equity issuance (raising material proceeds and increasing shares to ~196.6M). Continued use of equity-linked funding dilutes existing holders and signals persistent dependence on external capital, which can erode per-share economics and investor returns over time.
SELLAS Life Sciences Group News
SLS FAQ
What was Sellas Life Sciences Group’s price range in the past 12 months?
Sellas Life Sciences Group lowest stock price was $1.39 and its highest was $9.51 in the past 12 months.
What is Sellas Life Sciences Group’s market cap?
Sellas Life Sciences Group’s market cap is $1.46B.
When is Sellas Life Sciences Group’s upcoming earnings report date?
Sellas Life Sciences Group’s upcoming earnings report date is Aug 06, 2026 which is in 51 days.
How were Sellas Life Sciences Group’s earnings last quarter?
Sellas Life Sciences Group released its earnings results on May 12, 2026. The company reported -$0.05 earnings per share for the quarter, beating the consensus estimate of -$0.06 by $0.01.
Is Sellas Life Sciences Group overvalued?
According to Wall Street analysts Sellas Life Sciences Group’s price is currently Undervalued.
Does Sellas Life Sciences Group pay dividends?
Sellas Life Sciences Group does not currently pay dividends.
What is Sellas Life Sciences Group’s EPS estimate?
Sellas Life Sciences Group’s EPS estimate is -0.05.
How many shares outstanding does Sellas Life Sciences Group have?
Sellas Life Sciences Group has 186,032,580 shares outstanding.
What happened to Sellas Life Sciences Group’s price movement after its last earnings report?
Sellas Life Sciences Group reported an EPS of -$0.05 in its last earnings report, beating expectations of -$0.06. Following the earnings report the stock price went up 25.096%.
Which hedge fund is a major shareholder of Sellas Life Sciences Group?
Currently, no hedge funds are holding shares in SLS
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
SELLAS Life Sciences Group Stock Smart Score
Neutral
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Moderate Buy
Average Price Target:
$10.00 (143.31% Upside)
$10.00 (143.31% Upside)
Blogger Sentiment
Neutral
SLS Sentiment 50%
Sector Average ―
Sector Average ―
Hedge Fund Trend
Increased
By 88.2K Shares
Last Quarter.
Last Quarter.
Crowd Wisdom
Very Positive
Last 7 Days ▼ 1.4%
Last 30 Days ▲ 8.7%
Last 30 Days ▲ 8.7%
Technicals
SMA
Positive
20 days / 200 days
Momentum
374.54%
12-Months-Change
Fundamentals
Return on Equity
-47.12%
Trailing 12-Months
Asset Growth
226.63%
Trailing 12-Months
Company Description
Sellas Life Sciences Group
SELLAS Life Sciences Group, Inc. operates as a late-stage biopharmaceutical entity, dedicated to advancing novel cancer immunotherapies for various cancer indications across the United States. Its primary investigational product, galinpepimut-S (GPS), is a cancer immunotherapeutic agent engineered to target Wilms tumor 1. GPS is currently in Phase III clinical trials for acute myeloid leukemia and Phase 1/2 studies for ovarian cancer. Additionally, the company is progressing nelipepimut-S, an immunotherapy aimed at human epidermal growth factor receptor 2, which is undergoing Phase 2b clinical evaluation for early-stage breast cancer. A strategic collaboration with Merck & Co., Inc. is underway to assess GPS in combination with the PD1 blocker pembrolizumab, specifically within a Phase 1/2 clinical trial encompassing up to five distinct cancer indications, including both hematologic malignancies and solid tumors. Founded in 2012, SELLAS maintains its corporate headquarters in New York, New York.
SLS Stock 12 Month Forecast
Average Price Target
$10.00
▲(143.31% Upside)
Technical Analysis
Galectin Therapeutics
―
Voyager Therapeutics
―
Tiziana Life Sciences
―
Diamedica Therapeutics
―
Black Diamond Therapeutics
―
Ownership Overview
1.22% Insiders
6.32% Mutual Funds
1.96% Other Institutional Investors
78.49% Public Companies and Individual Investors